{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"ZBH","limit":50},"count":50,"signals":[{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":15,"context":"or officers to knowingly expose us to excessive enterprise risk. We believe that our compensation policies and practices do not encourage excessive risk-taking and are not reasonably likely to have a material adverse effect on us. Zimmer Biomet 19 CORPORATE GOVERNANCE | | | | | | | | | | | | | Corporate Governance CommitteeBetsy J. Bernard, Chair | | Other Committee Members:Robert A. Hagemann Maria Teresa Hil","filed_date":"2026-04-01","accession":"0001193125-26-135661","full_text":"https://origin.rootz.global/static/filing/0001193125-26-135661.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":26,"context":"erformance of the business internally, as well as with how management generally provides earnings guidance and reports the companys operating results to the investment community. In January 2025, we entered into a definitive agreement to acquire all outstanding shares of Paragon 28, a leading medical device company focused exclusively on the foot and ankle orthopedic segment. In early February, the Board approved the 2025 annual o","filed_date":"2026-04-01","accession":"0001193125-26-135661","full_text":"https://origin.rootz.global/static/filing/0001193125-26-135661.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":100,"match_count":67,"context":"etwork in the U.S. and other markets; shifts in the product category or regional sales mix of our products and services; the risks and uncertainties related to our ability to successfully execute our restructuring plans; risks and uncertainties relating to our ability to successfully execute on our product portfolio rationalization plans; control of costs and expenses; risks related to the ability to realize the an","filed_date":"2026-02-20","accession":"0001193125-26-059853","full_text":"https://origin.rootz.global/static/filing/0001193125-26-059853.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":100,"context":"s against our officers, employees or us. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively manufacturing, marketing and selling our products and could have a material adverse effect on our business, financial condition and results of operations. The FDA, in cooperation with U.S. Customs and Border Protection (CBP), administers controls over the import of medical devices into th","filed_date":"2026-02-20","accession":"0001193125-26-059853","full_text":"https://origin.rootz.global/static/filing/0001193125-26-059853.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":17,"context":"| 64 | | Senior Vice President, Chief Human Resources Officer | | | Sang Yi | | 63 | | Group President, Asia Pacific | | Mr. Tornos was appointed Chairman of the Board in May 2025. He was appointed President and Chief Executive Officer and a member of the Board of Directors in August 2023. Previously, he served as the Companys Chief Operating Officer since March 2021, as Group President, Global Businesses and the Americas from Dece","filed_date":"2026-02-20","accession":"0001193125-26-059853","full_text":"https://origin.rootz.global/static/filing/0001193125-26-059853.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":100,"match_count":46,"context":"ordingly, the only difference from the presentation above and our reportable operating segments are the geographic groupings. 4. Restructuring In February 2025, our management approved a new global restructuring program (the 2025 Restructuring Plan) intended to reduce costs and transform the way we operate. The 2025 Restructuring Plan is expected to result in total pre-tax restructuring charges of approximately $85","filed_date":"2025-11-05","accession":"0001193125-25-266884","full_text":"https://origin.rootz.global/static/filing/0001193125-25-266884.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":100,"match_count":46,"context":"ordingly, the only difference from the presentation above and our reportable operating segments are the geographic groupings. 4. Restructuring In February 2025, our management approved a new global restructuring program (the 2025 Restructuring Plan) intended to reduce costs and transform the way we operate. The 2025 Restructuring Plan is expected to result in total pre-tax restructuring charges of approximately $85","filed_date":"2025-08-07","accession":"0000950170-25-104989","full_text":"https://origin.rootz.global/static/filing/0000950170-25-104989.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":21,"context":"Conflicts | | | 61 | | | | SECTION 6.03. | | Enforceability | | | 61 | | | | SECTION 6.04. | | Governmental Approvals | | | 61 | | | | SECTION 6.05. | | Financial Statements; No Material Adverse Effect | | | 61 | | | | SECTION 6.06. | | Litigation, Compliance with Laws | | | 61 | | | | SECTION 6.07. | | Federal Reserve Regulations | | | 62 | | | | SECTION 6.08. | | Taxes | |","filed_date":"2025-06-30","accession":"0001193125-25-152694","full_text":"https://origin.rootz.global/static/filing/0001193125-25-152694.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":100,"match_count":45,"context":"ordingly, the only difference from the presentation above and our reportable operating segments are the geographic groupings. 4. Restructuring In February 2025, our management approved a new global restructuring program (the \"2025 Restructuring Plan\") intended to reduce costs and transform the way we operate. The 2025 Restructuring Plan is expected to result in total pre-tax restructuring charges of approximately $8","filed_date":"2025-05-05","accession":"0000950170-25-063509","full_text":"https://origin.rootz.global/static/filing/0000950170-25-063509.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":17,"context":"or officers to knowingly expose us to excessive enterprise risk. We believe that our compensation policies and practices do not encourage excessive risk-taking and are not reasonably likely to have a material adverse effect on us. Zimmer Biomet 19 CORPORATE GOVERNANCE | | | | | | | | | | | | | Corporate Governance CommitteeBetsy J. Bernard, Chair | | Other Committee Members:Christopher B. Begley Robert A. Hag","filed_date":"2025-04-14","accession":"0000950170-25-053494","full_text":"https://origin.rootz.global/static/filing/0000950170-25-053494.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":28,"context":"by Delaware Law | | | | 26 | Audit Committee Report | | | | | | 27-67 | | EXECUTIVE COMPENSATION | 81-82 | | OWNERSHIP OF OUR STOCK | | | | 27 | Proposal 3 Advisory Vote to Approve Named Executive Officer Compensation | | 81 | Security Ownership of Directors and Executive Officers | | | | 2828 | Compensation Discussion and AnalysisExecutive Summary | | 82 | Security Ownership of Certain Bene","filed_date":"2025-04-14","accession":"0000950170-25-053494","full_text":"https://origin.rootz.global/static/filing/0000950170-25-053494.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":100,"match_count":66,"context":"tors we need to support our business; shifts in the product category or regional sales mix of our products and services; the risks and uncertainties related to our ability to successfully execute our restructuring plans; control of costs and expenses; risks related to the satisfaction of the conditions to closing the proposed transaction with Paragon 28 (including the failure to obtain necessary regulatory approval","filed_date":"2025-02-25","accession":"0000950170-25-026604","full_text":"https://origin.rootz.global/static/filing/0000950170-25-026604.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":102,"context":"s against our officers, employees or us. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively manufacturing, marketing and selling our products and could have a material adverse effect on our business, financial condition and results of operations. The FDA, in cooperation with U.S. Customs and Border Protection (CBP), administers controls over the import of medical devices into th","filed_date":"2025-02-25","accession":"0000950170-25-026604","full_text":"https://origin.rootz.global/static/filing/0000950170-25-026604.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":20,"context":"r debt, including types of debt, maturity dates, interest rates, debt covenants and available revolving credit facilities, see Note 13 to our consolidated financial statements. 35 In January 2025, we entered into a definitive agreement to acquire all outstanding shares of Paragon 28, Inc (Paragon 28). The proposed transaction will require initial consideration of approximately $1.2 billion to be paid at closing, which is expected t","filed_date":"2025-02-25","accession":"0000950170-25-026604","full_text":"https://origin.rootz.global/static/filing/0000950170-25-026604.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":19,"context":"such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure so to qualify or to be in good standing would not have a material adverse effect on the business, business prospects, financial condition or results of operations of the Company and its subsidiaries considered as a whole (a Material Adverse Effect). (j) Each of the Companys subs","filed_date":"2025-02-18","accession":"0001193125-25-028618","full_text":"https://origin.rootz.global/static/filing/0001193125-25-028618.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":19,"context":"such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure so to qualify or to be in good standing would not have a material adverse effect on the business, business prospects, financial condition or results of operations of the Company and its subsidiaries considered as a whole (a Material Adverse Effect). (j) Each of the Companys subs","filed_date":"2024-11-19","accession":"0001193125-24-261733","full_text":"https://origin.rootz.global/static/filing/0001193125-24-261733.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":100,"match_count":49,"context":"ordingly, the only difference from the presentation above and our reportable operating segments are the geographic groupings. 4. Restructuring In December 2023, our management approved a new global restructuring program (the 2023 Restructuring Plan) intended to optimize our cost structure and drive greater efficiencies throughout the company. The 2023 Restructuring Plan is expected to result in total pre-tax restruc","filed_date":"2024-10-30","accession":"0000950170-24-118959","full_text":"https://origin.rootz.global/static/filing/0000950170-24-118959.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":19,"context":"such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure so to qualify or to be in good standing would not have a material adverse effect on the business, business prospects, financial condition or results of operations of the Company and its subsidiaries considered as a whole (a Material Adverse Effect). (j) Each of the Companys subs","filed_date":"2024-08-14","accession":"0001193125-24-200634","full_text":"https://origin.rootz.global/static/filing/0001193125-24-200634.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":100,"match_count":59,"context":", our suppliers, customers or payors, either alone or in combination with other risks on our business and operations; the risks and uncertainties related to our ability to successfully execute 1 our restructuring plans; control of costs and expenses; our ability to attract, retain and develop the highly skilled employees, senior management, independent agents and distributors we need to support our business; the p","filed_date":"2024-08-07","accession":"0000950170-24-092996","full_text":"https://origin.rootz.global/static/filing/0000950170-24-092996.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":100,"match_count":51,"context":"ordingly, the only difference from the presentation above and our reportable operating segments are the geographic groupings. 4. Restructuring In December 2023, our management approved a new global restructuring program (the 2023 Restructuring Plan) intended to optimize our cost structure and drive greater efficiencies throughout the company. The 2023 Restructuring Plan is expected to result in total pre-tax restruc","filed_date":"2024-08-07","accession":"0000950170-24-092746","full_text":"https://origin.rootz.global/static/filing/0000950170-24-092746.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":21,"context":"Conflicts | | | 59 | | | | SECTION 6.03. | | Enforceability | | | 59 | | | | SECTION 6.04. | | Governmental Approvals | | | 60 | | | | SECTION 6.05. | | Financial Statements; No Material Adverse Effect | | | 60 | | | | SECTION 6.06. | | Litigation, Compliance with Laws | | | 60 | | | | SECTION 6.07. | | Federal Reserve Regulations | | | 60 | | | | SECTION 6.08. | | Taxes | |","filed_date":"2024-07-01","accession":"0001193125-24-173303","full_text":"https://origin.rootz.global/static/filing/0001193125-24-173303.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":100,"match_count":47,"context":"ordingly, the only difference from the presentation above and our reportable operating segments are the geographic groupings. 4. Restructuring In December 2023, our management approved a new global restructuring program (the 2023 Restructuring Plan) intended to optimize our cost structure and drive greater efficiencies throughout the company. The 2023 Restructuring Plan is expected to result in total pre-tax restruc","filed_date":"2024-05-02","accession":"0000950170-24-052097","full_text":"https://origin.rootz.global/static/filing/0000950170-24-052097.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"basis and is not opposed in concept to combining these roles in the future. The Chairman provides leadership to the Board and works with the Board to define its structure and activities in the fulfillment of its responsibilities. In discharging his or her duties, the non-executive Chairman will: preside at meetings of the Board and shareholders; establish processes to assist the Board in the effi","filed_date":"2024-03-27","accession":"0000950170-24-037305","full_text":"https://origin.rootz.global/static/filing/0000950170-24-037305.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":26,"context":"or officers to knowingly expose us to excessive enterprise risk. We believe that our compensation policies and practices do not encourage excessive risk-taking and are not reasonably likely to have a material adverse effect on us. Zimmer Biomet 20 CORPORATE GOVERNANCE | | | | | | | | | | | | | Corporate Governance CommitteeBetsy J. Bernard, Chair | | Other Committee Members:Christopher B. Begley Robert A. Hag","filed_date":"2024-03-27","accession":"0000950170-24-037305","full_text":"https://origin.rootz.global/static/filing/0000950170-24-037305.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":35,"context":"l be voting on four matters at our 2024 annual meeting election of directors, ratification of the appointment of PricewaterhouseCoopers LLP, approval, on an advisory basis, of the compensation of our named executive officers and approval of the amended Employee Stock Purchase Plan. I encourage you to read the pages that follow and ask for your support on these matters. This letter highlights some of the actions we have","filed_date":"2024-03-27","accession":"0000950170-24-037305","full_text":"https://origin.rootz.global/static/filing/0000950170-24-037305.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":100,"match_count":66,"context":"es; the effects of business disruptions, either alone or in combination with other risks on our business and operations; the risks and uncertainties related to our ability to successfully execute our restructuring plans; control of costs and expenses; our ability to attract, retain and develop the highly skilled employees, senior management, independent agents and distributors we need to support our business; the p","filed_date":"2024-02-23","accession":"0000950170-24-019353","full_text":"https://origin.rootz.global/static/filing/0000950170-24-019353.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":99,"context":"s against our officers, employees or us. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively manufacturing, marketing and selling our products and could have a material adverse effect on our business, financial condition and results of operations. The FDA, in cooperation with U.S. Customs and Border Protection (CBP), administers controls over the import of medical devices into th","filed_date":"2024-02-23","accession":"0000950170-24-019353","full_text":"https://origin.rootz.global/static/filing/0000950170-24-019353.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":19,"context":"h on hand and proceeds from a draw on our revolving credit facility, to repay senior notes due in 2022 which had an outstanding principal balance of $750.0 million. In connection with the spinoff, we entered into definitive agreements with ZimVie that, among other things, set forth the terms and conditions of the separation and distribution. These agreements include a Transition Services Agreement (the TSA), a Transition Manufact","filed_date":"2024-02-23","accession":"0000950170-24-019353","full_text":"https://origin.rootz.global/static/filing/0000950170-24-019353.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":19,"context":"such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure so to qualify or to be in good standing would not have a material adverse effect on the business, business prospects, financial condition or results of operations of the Company and its subsidiaries considered as a whole (a Material Adverse Effect). (j) Each of the Companys subs","filed_date":"2023-12-01","accession":"0001193125-23-287490","full_text":"https://origin.rootz.global/static/filing/0001193125-23-287490.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":100,"match_count":32,"context":"Accordingly, the only difference from the presentation above and our reportable operating segments are the geographic groupings. 5. Restructuring In December 2021, our management approved a global restructuring program (the “2021 Restructuring Plan”) intended to further reduce costs and to reorganize our global operations in preparation for the spinoff of ZimVie. The 2021 Restructuring Plan is expecte","filed_date":"2023-11-07","accession":"0000950170-23-060232","full_text":"https://origin.rootz.global/static/filing/0000950170-23-060232.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":100,"match_count":31,"context":"Accordingly, the only difference from the presentation above and our reportable operating segments are the geographic groupings. 5. Restructuring In December 2021, our management approved a global restructuring program (the “2021 Restructuring Plan”) intended to further reduce costs and to reorganize our global operations in preparation for the spinoff of ZimVie. The 2021 Restructuring Plan is expecte","filed_date":"2023-08-01","accession":"0000950170-23-036456","full_text":"https://origin.rootz.global/static/filing/0000950170-23-036456.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":21,"context":"Conflicts | | | 59 | | | | SECTION 6.03. | | Enforceability | | | 59 | | | | SECTION 6.04. | | Governmental Approvals | | | 59 | | | | SECTION 6.05. | | Financial Statements; No Material Adverse Effect | | | 59 | | | | SECTION 6.06. | | Litigation, Compliance with Laws | | | 60 | | | | SECTION 6.07. | | Federal Reserve Regulations | | | 60 | | | | SECTION 6.08. | | Taxes | |","filed_date":"2023-07-10","accession":"0001193125-23-184743","full_text":"https://origin.rootz.global/static/filing/0001193125-23-184743.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":100,"match_count":32,"context":"ordingly, the only difference from the presentation above and our reportable operating segments are the geographic groupings. 5. Restructuring In December 2021, our management approved a new global restructuring program (the “2021 Restructuring Plan”) intended to further reduce costs and to reorganize our global operations in preparation for the spinoff of ZimVie. The 2021 Restructuring Plan is expecte","filed_date":"2023-05-02","accession":"0000950170-23-016663","full_text":"https://origin.rootz.global/static/filing/0000950170-23-016663.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":25,"context":"Firm | | | | | 25 | | Audit and Non-Audit Fees | | | | | 25 | | Audit Committee Report | | | 26-78 | | | | EXECUTIVE COMPENSATION | | | | 26 | | Proposal 3 Advisory Vote to Approve Named Executive Officer Compensation | | | | | 27 | | Proposal 4 Advisory Vote on the Frequency of Say on Pay Votes | | | | | | | | | | | | 28 | | Compensation Discussion and Analysis | | | | | 28 | | Ex","filed_date":"2023-03-30","accession":"0001193125-23-085733","full_text":"https://origin.rootz.global/static/filing/0001193125-23-085733.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":100,"match_count":58,"context":"sruptions such as the COVID-19 pandemic, either alone or in combination with other risks on our business and operations; the risks and uncertainties related to our ability to successfully execute our restructuring plans; control of costs and expenses; our ability to attract, retain and develop the highly skilled employees, senior management, independent agents and distributors we need to support our business; the p","filed_date":"2023-02-24","accession":"0000950170-23-004264","full_text":"https://origin.rootz.global/static/filing/0000950170-23-004264.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":71,"context":"s against our officers, employees or us. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively manufacturing, marketing and selling our products and could have a material adverse effect on our business, financial condition and results of operations. For information regarding a warning letter and certain Form 483 inspectional observations that we are addressing at a single Zimmer Bio","filed_date":"2023-02-24","accession":"0000950170-23-004264","full_text":"https://origin.rootz.global/static/filing/0000950170-23-004264.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":17,"context":"proceeds from a draw on our revolving credit facility, to repay our 3.150% Senior Notes due 2022 which had an outstanding principal balance of $750.0 million. Also, in connection with the spinoff, we entered into definitive agreements with ZimVie that, among other things, set forth the terms and conditions of the separation and distribution. The agreements set forth the principles and actions taken or to be taken in connection wi","filed_date":"2023-02-24","accession":"0000950170-23-004264","full_text":"https://origin.rootz.global/static/filing/0000950170-23-004264.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":100,"match_count":43,"context":"above. Accordingly, the only difference from the presentation above and our reportable operating segments are the geographic groupings. 5. Restructuring In December 2021, we initiated a new global restructuring program (the “2021 Restructuring Plan”) to reorganize our operations in preparation for the planned spinoff of ZimVie with an objective of reducing costs. The 2021 Restructuring Plan is expecte","filed_date":"2022-11-02","accession":"0000950170-22-021220","full_text":"https://origin.rootz.global/static/filing/0000950170-22-021220.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":21,"context":"Conflicts | | | 57 | | | | SECTION 6.03. | | Enforceability | | | 58 | | | | SECTION 6.04. | | Governmental Approvals | | | 58 | | | | SECTION 6.05. | | Financial Statements; No Material Adverse Effect | | | 58 | | | | SECTION 6.06. | | Litigation, Compliance with Laws | | | 58 | | | | SECTION 6.07. | | Federal Reserve Regulations | | | 59 | | | | SECTION 6.08. | | Taxes | |","filed_date":"2022-08-22","accession":"0001193125-22-226467","full_text":"https://origin.rootz.global/static/filing/0001193125-22-226467.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":100,"match_count":42,"context":"ove. Accordingly, the only difference from the presentation above and our reportable operating segments are the geographic groupings. 11 5. Restructuring In December 2021, we initiated a new global restructuring program (the “2021 Restructuring Plan”) to reorganize our operations in preparation for the planned spinoff of ZimVie with an objective of reducing costs. The 2021 Restructuring Plan is expecte","filed_date":"2022-08-02","accession":"0000950170-22-013875","full_text":"https://origin.rootz.global/static/filing/0000950170-22-013875.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":100,"match_count":47,"context":"heCOVID-19pandemic; the failure of elective surgical procedures to recover at the levels or on the timeline anticipated; the risks and uncertainties related to our ability to successfully execute our restructuring plans; our ability to attract, retain and develop the highly skilled employees we need to support our business; the risks and uncertainties associated with the spinoffof ZimVie, including, without limitat","filed_date":"2022-06-22","accession":"0001193125-22-178777","full_text":"https://origin.rootz.global/static/filing/0001193125-22-178777.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":100,"match_count":37,"context":"above.Accordingly, the only difference from the presentation above and our reportable operating segments are the geographic groupings. 11 5.Restructuring In December 2021, we initiated a new global restructuring program (the 2021 Restructuring Plan) to reorganize our operations in preparation for the planned spinoff of ZimVie with an objective of reducing costs.The 2021 Restructuring Plan is expected to result in to","filed_date":"2022-05-05","accession":"0001564590-22-018250","full_text":"https://origin.rootz.global/static/filing/0001564590-22-018250.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":22,"context":"Firm | | | | | 25 | | Audit and Non-Audit Fees | | | | | 25 | | Audit Committee Report | | | 26-64 | | | | EXECUTIVE COMPENSATION | | | | 26 | | Proposal 3 Advisory Vote to Approve Named Executive Officer Compensation | | | | | | | | | | | | 27 | | Compensation Discussion and Analysis | | | | | 27 | | Executive Summary | | | | | 30 | | Key Executive Compensation Program Practices |","filed_date":"2022-03-29","accession":"0001193125-22-088235","full_text":"https://origin.rootz.global/static/filing/0001193125-22-088235.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":100,"match_count":55,"context":"he COVID-19 pandemic the failure of elective surgical procedures to recover at the levels or on the timeline anticipated the risks and uncertainties related to our ability to successfully execute our restructuring plans our ability to attract, retain and develop the highly skilled employees we need to support our business the risks and uncertainties associated with the planned spinoff of ZimVie Inc., including, wit","filed_date":"2022-02-25","accession":"0001564590-22-007160","full_text":"https://origin.rootz.global/static/filing/0001564590-22-007160.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":52,"context":"to the U.S. Department of Justice (DOJ).Any adverse regulatory action, depending on its magnitude, may restrict us from effectively manufacturing, marketing and selling our products and could have a material adverse effect on our business, 8 financial condition and results of operations.For information regarding certain warning letters and Form 483 inspectional observations that we are addressing, see Note 21 to our c","filed_date":"2022-02-25","accession":"0001564590-22-007160","full_text":"https://origin.rootz.global/static/filing/0001564590-22-007160.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":12,"context":"ent, Europe, Middle East and Africa | | | Lori Winkler | | 60 | | Senior Vice President, Chief Human Resources Officer | | | Sang Yi | | 59 | | President, Asia Pacific | | Mr. Hanson was appointed President and Chief Executive Officer and a member of the Board of Directors in December 2017.He was subsequently named Chairman of the Board of Directors in May 2021.Previously, Mr. Hanson served as Executive Vice President and Presiden","filed_date":"2022-02-25","accession":"0001564590-22-007160","full_text":"https://origin.rootz.global/static/filing/0001564590-22-007160.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":100,"match_count":35,"context":"rrent expectations due to the COVID-19 pandemic, if competing or alternative technologies emerge, if market conditions or future cash flow estimates for our dental business decline, or as a result of restructuring initiatives pursuant to which we reorganize our reporting units, we could be required to record additional impairment charges. Any write-off of a material portion of our goodwill or unamortized intangible asset","filed_date":"2022-02-22","accession":"0001193125-22-048557","full_text":"https://origin.rootz.global/static/filing/0001193125-22-048557.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":66,"context":"en by local governments and healthcare authorities globally, including the deferral of elective surgical procedures and social distancing measures, have had, and we expect them to continue to have, a significant adverse effect on our financial condition, results of operations and cash flows. These disruptions have resulted in the following outcomes, among other unfavorable outcomes: | | | | lower revenues, profits and","filed_date":"2022-02-22","accession":"0001193125-22-048557","full_text":"https://origin.rootz.global/static/filing/0001193125-22-048557.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":37,"context":"mation. We adopted this standard as of January 1, 2020. Adoption of this standard required the modified retrospective transition method, which resulted in a cumulative-effect adjustment to net parent investment of $1.0 million. The F-15 adoption primarily impacted our trade receivables. Our concentrations of credit risks are limited due to the large number of customers and their dispersion across a number of geographic a","filed_date":"2022-02-22","accession":"0001193125-22-048557","full_text":"https://origin.rootz.global/static/filing/0001193125-22-048557.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZBH","company":"ZIMMER BIOMET HOLDINGS, INC.","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":19,"context":"such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure so to qualify or to be in good standing would not have a material adverse effect on the business, business prospects, financial condition or results of operations of the Company and its subsidiaries considered as a whole (a Material Adverse Effect). (j) Each of the Companys subs","filed_date":"2021-11-18","accession":"0001193125-21-333829","full_text":"https://origin.rootz.global/static/filing/0001193125-21-333829.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"a2640f6deca70086af7db35f6c0092eb5f1fe121b1b9616dbf56e6468b80d9b2","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"ab410028cd52b627b07689c38c3fa73b323ad38e041dbdf05984b92912ba2964","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":43,"hourly_limit":500,"remaining":457,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}